Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors within vivoefficacy in a pain model

Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats

(2010) Timothy K. Y. Kaan et al.   BRAIN

AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist

(2010) Joel R Gever et al.   BRITISH JOURNAL OF PHARMACOLOGY

Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update

(2010) Robert H. Dworkin et al.   MAYO CLINIC PROCEEDINGS

Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain

(2009) Alam Jahangir et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain

(2009) David S. Carter et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Mechanism of action of species-selective P2X7 receptor antagonists

(2009) Anton D Michel et al.   BRITISH JOURNAL OF PHARMACOLOGY

Signaling at Purinergic P2X Receptors

(2008) Annmarie Surprenant et al.   Annual Review of Physiology

Investigation into the role of P2X3/P2X2/3 receptors in neuropathic pain following chronic constriction injury in the rat: an electrophysiological study

(2006) Caroline J Sharp et al.   BRITISH JOURNAL OF PHARMACOLOGY